During the last quarter of the past century, the leading role the endocrine and nervous systems had on the regulation of vasomotion, shifted towards a more paracrine-based regulation. This begun with the recognition of endothelial cells as active players of vascular control, when the vessel's intimal layer was identified as the main source of prostacyclin and was followed by the discovery of an endothelium-derived smooth muscle cell relaxing factor (EDRF). The new position acquired by endothelial cells prompted the discovery of other endothelium-derived regulatory products: vasoconstrictors, generally known as EDCFs, endothelin, and other vasodilators with hyperpolarizing properties (EDHFs). While this research was taking place, a quest for the discovery of the nature of EDRF carried back to a research line commenced a decade earlier: the recently found intracellular messenger cGMP and nitrovasodilators. Both were smooth muscle relaxants and appeared to interact in a hormonal fashion. Prejudice against an unconventional gaseous molecule delayed the acceptance that EDRF was nitric oxide (NO). When this happened, a new era of research that exceeded the vascular field commenced. The discovery of the pathway for NO synthesis from L-arginine involved the clever assembling of numerous unrelated observations of different areas of knowledge. The last ten years of research on the paracrine regulation of the vascular wall has shifted to perivascular fat (PVAT), which is beginning to be regarded as the fourth layer of the vascular wall. Starting with the discovery of an adipose-derived relaxing substance (ADRF), the role that different adipokines have on the paracrine control of vasomotion is now filling the research activity of many vascular pharmacology labs, and surprising interactions between the endothelium, PVAT and smooth muscle are being unveiled.
Introduction
During much part of last century, vasomotion, i.e.: change in the vessel's diameter, was thought to be mostly regulated by the autonomous nervous system and hormones released by specific glands. An alternative to this was proposed during the late forties and early fifties by Jimenez-Díaz and colleagues who, by means of cross-circulation experiments, demonstrated the endocrine role of the vessel wall [1, 2] . However, no hormonal function was assigned to specific vascular structures until much later. The concept of paracrine secretion was introduced by this time because it was convenient for distinguishing locally-acting gastrointestinal hormones from systemically-acting hormones [3] but the term was not of general use in physiology as it is today. The first substance able to dilate vascular smooth muscle synthesized and released by the vessels themselves was described in the mid-seventies [4] . This was prostacyclin [5] . With the turn of the decade, the endothelial cell of the vascular intimal layer was specifically pinpointed as essential for the relaxation of adjacent smooth muscle cells [6] . The conception of an endothelial cell releasing substances that preferentially affect nearby smooth muscle cells, i.e.: paracrine regulation, was extended during the eighties to a variety of substances, including prostacyclin and nitric oxide (NO), which is probably the one that has received more attention. With this panorama in sight, the endothelium was proposed as a real endocrine organ [7] . While endothelial cells had gained a prominent role as regulators of vasomotion and various other functions, other vascular cells timidly obtained the qualification of paracrine regulatory cells. The first to break the ice was not, as one would initially think, the anatomically immediate adventitial fibroblast, but rather, the outermost perivascular fat tissue [8] . This opening work [8] had to wait until 2002, when the burst of perivascular fat research took place [9] . In the meanwhile, new roles for adventitial cells as a source of substances began to be assigned [10] .
In this review we will search for the seminal advances and pioneering work that yielded the knowledge we have today on the major paracrine elements controlling vascular smooth muscle contraction or relaxation. These are, the endothelium-derived substances: NO, prostacyclin, contracting and hyperpolarizing factors and the, relatively newer, substances released by the adventitia and perivascular adipose tissue. A chronological order of reporting has been given priority to a more academic order. Occasionally, this can appear odd at reading. For example, for the endothelium-derived relaxing factor (EDRF)-NO topic, NO is not explained right away after EDRF because nearly a decade of contracting and hyperpolarizing factor research took place in between. In some occasions, the preliminary work necessary for a subsequent discovery took place quite a long time and with, apparently, little connection with the latter. In many instances, various groups published so closely in time to the report traditionally recognized as the first and principal that it is easy to conceive that work aimed at the same target was being carried out in parallel. Often, an idea is more or less vaguely suggested in preliminary works and definitely demonstrated by the same or other authors in subsequent reports. In the present review we have tried to quote every report related or involved in a discovery and not solely that generally recognized as the first one.
Early approaches to the paracrine role of the intima
The existence of endothelial cells was first reported by von Reckinghausen in 1860. The German pathologist managed to observe the endothelial lining of the vessel's inner wall by staining the edges of endothelial cells with silver nitrate [11] . From then on and for many years, the endothelium was regarded, more or less, as a tapestry lacking any functional role. For example, at the sight of some of the first electron microscope plates, endothelial cells were literally described as ". . .to form little more than a sheet of nucleated cellophane" [12] . Nevertheless, early electron microscopist, Rhodin, intuitively suggested that ". . .humoral transmitter substances [. . .] are picked up by the luminal cell membrane of the endothelial cell and passed on to the smooth muscle cells. . .". This seemed to be a prelude of some kind of regulatory function [13] . Furthermore, some pharmacologists reported shortly later intriguing findings that were not consistent with a passive notion of endothelial function. Bevan & Duckles, for instance, realized that noradrenaline bound to glass microbeads present in the vascular lumen and, therefore, unable to reach the smooth muscle wall, did elicit a contractile effect [14] . They reasoned that the only way this could happen was if endothelial cells had surface receptors to the amine and endothelial cells had a mechanism of spread towards the underlining muscle cells. They raised the possibility that circulating drugs initiate changes in the tone of vascular smooth muscle by an action on the intimal endothelial cells [14] by means of receptors on these cells that would be the first to detect blood-borne vasoactive substances [15] . In those years, the existence of receptors to a variety of vasoactive agents on endothelial cell membranes and linked to cAMP and cGMP was already known [16] . Thus, the scenario for discovery was ready.
Another suggestive finding, both for the putative paracrine roles of intimal and adventitial cells, was the observation that the effects of contractile amines was very different when applied via the intimal side or through the adventitial side [17, 18] . Vessels were systematically more sensitive when exposed through the intima. Among others, one of the explanations they considered was that the different vascular layers the drug had to cross, intima and adventitia, carried out some sort of active role. Unfortunately, this suspected active role was tested only in the adventitia, by specifically removing it [19] , but not in the intimal endothelial cells, as Furchgott did very shortly later [6] . They missed an opportunity for an important discovery.
Prostacyclin
Prostacyclin, together with thromboxane A 2 (TXA 2 ) and various prostaglandins are synthesized from arachidonic acid, a fatty acid derived from membrane phospholipids. Endoperoxides are intermediate molecules between arachidonic acid and the various prostanoids. Enzymes cyclooxygenase I and II catalyze the formation of these endoperoxides. Prostacyclin was discovered in 1976 by the group led by Vane [4] . Vane's interest in prostaglandins dates back to the late sixties studying anaphylactic responses of perfused lungs from sensitized guinea pigs and the different substances thereby released, such as histamine, slow-reacting substance in anaphylaxis (SRS-A) and also prostaglandin-like substances [20] . One of these was the so-called, "rabbit aorta contracting substance" or RCS, because it caused a strong contraction of strips of rabbit aorta. This was later identified as TXA 2 [21] , a powerful proaggregatory and vasoconstritive mediator, and the synthesizing enzyme, "thromboxane synthetase", was isolated from the "microsomal" fraction of platelets [22] . Eventually, the group began to study other tissues in an attempt to find alternative sources of TXA 2 generation. John Vane explains how they came across an unexpected finding [23] : "It was Moncada's suggestion that we should look into the biosynthetic system of vascular tissue, since vascular endothelium and platelets might share some structural features. Indeed, after several weeks of work we found that microsomal fractions of pig aorta [. . .] did not generate classical prostaglandins". The prostaglandin found in the vascular tissue, definitely was not TXA 2, but a substance with opposite properties: an anti-aggregating and vasodilator substance. It did not take too long until the chemical structure of the The first to attribute a functional role to the endothelium were early prostacyclin researchers showing that endothelial cells are the most important, if not the only source of this vasoactive eicosanoid [26, 27] . The intimal layer, which accounts for 5% of the calculated weight, produced about 40% of the total vessel's prostacyclin. The other layers contribute to the 60% prostacyclin left, but represent 95% of the artery's weight. Modified from Moncada et al. [26] .
new prostanoid was identified and renamed prostacyclin (PGI 2 ) [24] . It was also shown that the actions of prostacyclin are mediated by the adenylate cyclase/cyclic AMP pathway [25] and that, with a half-life long enough to reach distant targets, it could be regarded as a circulating hormone as well [5] . The first report on the newly discovered prostacyclin, still called PGX [4] , was remarkably mature in that today's well established concepts of physiology textbooks on the role of platelets and endothelial cells in hemostasis were already stated in this seminal paper. Especially relevant for the topic of the present review is that this paper also put forward the notion of a paracrine control of the tone of the vessel wall: "The fact that PGX is locally generated in the arterial wall and can relax smooth muscle also suggests that it plays a part in the local control of vascular tone". Shortly after this publication, the differential formation of prostacyclin by the different layers of the vessel wall was reported by this group [26] showing this is highest in the endothelial layer, thus providing the endothelium for the first time a leading role in the local control of vascular tone (Fig. 1) . Still, and maybe confounded by the fact the media and adventitia also released some prostacyclin [26] , the notion of an endothelially-centered control of vascular tone, could not be established. Ironically, another group publishing a little bit later was unable to detect prostacyclin release from smooth muscle or any other cell studied but endothelial cells [27] . If Vane's group had failed to find prostacyclin synthesis in the media, possibly the leadership of the endothelial cell had become earlier.
Endothelium-derived relaxing factor
In the immediate years following Vane's publications, the production of prostacyclin by the intimal or other vascular layers was mostly observed from the point of view of the anti-aggregating properties of the new prostaglandin able to counterbalance platelets' TXA 2 . From this angle, an endothelial damage was regarded as a hemostatic rather than a vasomotor threat. Thus, experimentation on vascular pharmacology was still carried out ignoring the endothelium. The first to change this scenario were Furchgott and Zawadszki with the publication in 1980 of "The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine" [6] . This paper was very remarkable in that in a single seminal report, providing unequivocal experimental evidence, demonstrated that acetylcholine required the presence of an intact endothelium to exert vasodilatory effects on the adjacent smooth muscle (Fig. 2) . Also that, via receptors on the endothelial cells, acetylcholine stimulates the release of a transferable substance which causes relaxation of the vessel wall. For these reasons, this work became the major milestone for vascular pharmacology and physiology research and was the most cited original paper in this field (6569 citations). Interestingly, Furchgott admits that the finding was quite accidental [28] : ". . .in the very first experiment of this planned series in May 1978, my technician did not follow my directions correctly: [. . .] he tested carbachol for its contracting activity before rather than after (as prescribed in the directions) washout of a previous test dose of norepinephrine. The response to carbachol was not a contraction, but was a partial relaxation [. . .]. Acetylcholine was then tested. It too produced relaxation of the aortic preparation precontracted with norepinephrine. This was the first time that I had ever observed relaxation of rabbit aorta in response to muscarinic agonists over the many years that I had been using this blood vessel. . .". They were expecting acetylcholine to contract, but by mistake the technician added the cholinergic agonist on top of an artery that should not have been precontracted. To Furchgott's surprise, a relaxation took place. Indeed, acetylcholine had shown vascular contractile responses in vitro since ever tested [29] . Still, Furchgott was conscious and that, for unknown reasons, vasodilator responses to acetylcholine had been occasionally detected [30] and, more importantly, that acetylcholine in vivo causes vasodilation [31] . The key to understand how Furchgott suspected that the answer was in the endothelial cells relies on the fact that in that set of experiments, they used intact aortic rings instead of spiral strips. Normally, he cut the arterial strips in a helical fashion and then he measured the force attained by hooking the edges to the myograph devise. To facilitate the cutting procedure he (and most pharmacologists) systematically introduced a wire through the lumen of the arteries, unaware that the endothelium was being damaged or removed. In fact, still today, introducing a rod or similar is a conventional procedure to deendothelialize a vessel. This was their regular procedure, but not the day the technician erred, in which an intact ring was tested. The original recording of the serendipitous finding can be found in ref. 28 . A preliminary report on these findings, prior to the 1980 paper, was an abstract from a 1979 meeting [32] in which, surprisingly, he revealed too many clues of the discovery.
Very shortly after Furchgott & Zawadszki's paper, a couple of groups corroborated the endothelium findings. De Mey & Vanhoutte described the role of the intima in various responses including cholinergic, purinergic and thrombin relaxations [33, 34] . This last paper started the listing of substances that elicit vasodilation via the endothelium and initiated the speculations on the nature of the endothelium-to-smooth muscle signals causing relaxation. Another report published nearly at the same time was that of Altura and Chand who were concerned about the unmatched in vitro versus in vivo effects of some agonists, in this case, kinins [35] . A year later, Furchgott, also interested in the endothelial mechanisms of bradykinin, reached similar conclusions as those of Altura and Chand on the endothelium-dependency of the kinin's action [36] . In this paper, Furchgott introduced for the first time the term "endothelium-derived relaxing factor" and its acronym "EDRF" to refer to a substance released from endothelial cells and able to relax the muscle. Substance P was also added to the growing list of hormones, which relax via endothelium. Another novelty of this paper was the first report of EDRF in human arteries. Furchgott's group also provided the first preliminary insights on the calcium-dependency of EDRF by examining the effects of the calcium ionophore A23187 on the endothelium-dependent relaxations [37] , an issue that was later investigated in more depth [38] . Seminal experiments performed by Furchgott and Zawadzki led, beyond any doubt, to the conclusion that endothelial cells, upon acetylcholine stimulation, release in a paracrine manner a substance that reaches smooth muscle cells to relax them (EDRF). Arteries were cut along and attached to a myograph. A, B and C represent various vascular arrangements and D is the so-called "sandwich" vascular preparation that definitely proved that intact artery 1 supplied with a relaxing factor deendothelialized artery 2 (smooth muscle 2). Author's micrographs of intact and deendothelialized arteries stained with silver nitrate have been used to exemplify the different myographical preparations. Note alignment of endothelial and smooth muscle cells with respect to myograph orientation. Pre-contraction with noradrenaline and eventual contractions to acetylcholine in rubbed strips have been omitted for simplicity. Acetylcholine was added in cumulative doses from 10 −8 to 10 −5 M.
Endothelium-derived constrictor factor
The realization of the existence of endothelium-dependent vasoconstriction took place early after Furchgott's publication and was somehow linked to the discovery of EDRF. Possibly the main difference was that the finding of EDRF was serendipitous in nature and the uncovering of the existence of the constrictor counterpart took part under a specific rationale: the attempt to clarify why in some instances acetylcholine relaxed a vessel, and contracted in others. Vanhoutte and De Mey were studying the mechanisms involved in the unexplained relaxations to acetylcholine in certain set-ups. One of these was anoxia, which they knew from previous studies that is able to augment catecholamine-induced contractile responses. Just before the publication of Furchgott's 1980 paper, they found that anoxia abolished the relaxing responses to acetylcholine [39] . Once knowing about the role of endothelial cells from Furchgott's studies, they took up the topic and published a short report which, in addition to confirming the obligatory roles of the endothelium, they also indicated that the augmented catecholamine contractile responses caused by subjecting the vessels to hypoxic conditions depended on the preservation of a functional endothelium [40] . The notion that the endothelium contributes, not solely to smooth muscle relaxation, but in some instances, to contractile responses was matured in following studies [41] and finally, the first evidence that anoxia causes the release of a diffusible vasoconstrictor substance from endothelial cells, was published by Vanhoutte and Rubanyi in 1985 [42] .
By the same time, Rubanyi together with Hickey and other colleagues were also working on a bioassay system aimed to identify the chemical nature of EDRF. They worked in a bioassay set-up in which the donors of the relaxing factor were cultured endothelial cells and the detectors were luminally rubbed arterial rings challenged with the medium from the endothelial culture.
Against expectations, what they found were not relaxations but, instead, that the acceptor rings consistently contracted. They pursued the studies trying to uncover the nature of the transferable substance and found that the contracting agent was compatible with a polypeptide [43] . This was the prelude of endothelin, the name Yanagisawa and his colleagues decided to give to the peptidic vasoconstrictor present in the endothelial culture medium once purified and sequenced [44] . Before this, the peptidic nature of the vasoconstrictor reported by the Hickey group was confirmed by Gillespie et al. who introduced the acronym EDCF in the literature to distinguish it from EDRF [45] . In a nice review published a few years ago, Rubanyi admits that the peptidic substance they discovered was nearly named "endotensin", but unfortunately, this was discarded in the reviewing process of the manuscript [46] and it ended up being called endothelin [44] .
In parallel to the endothelin work, Vanhoutte kept working on the lines initiated with hypoxia. He did not believe that endothelin was the only answer to the endothelium-dependent contractions [47] . One of the lines started with a 1985 paper showing that endothelial cyclooxygenase generates vasoconstrictor prostaglandins [48] , which were specifically ascribed to TXA 2 in a following paper by Altiere and coworkers [49] . Shortly afterwards, Lüscher published his classic paper for endothelial dysfunction showing that in the aorta of hypertensive rats, and due to an excess in vasoconstrictor prostaglandins, acetylcholine causes endothelium-dependent contractions rather than relaxations [50] .
During the following years Vanhoutte's group was engaged in a quest to pinpoint the contractile prostaglandin. Also, they embarked in a second line of research that introduced reactive oxygen species in the pathway of prostaglandins and the endothelium-dependent contractions. This line started rather categorical, proposing superoxide anion as EDCF [51] . This was not the first report on reactive oxygen species, prostanoids and vasoconstriction. It was already known that endothelial cells generate superoxide [52] and a few years before, Tate and others [6, [126] [127] [128] , n Katsuki '77a; Arnold '77, [106, 107] , o Katsuki '77b*; Kukovetz '79 [110, 112] , p Gordon '83 [67] , q Edwards '98 [68] , r Chen '88 [70] , s Hickey '85; Yanagisawa '88 [43, 44] . *Tracheal smooth muscle, which was tested before vascular smooth muscle.
reported that oxygen metabolites cause vasoconstriction of pulmonary arteries via TXA 2 [53] . After the start-up of the superoxide line, numerous publications trying to elucidate the link between endothelial activation, oxygen species generation, prostaglandin synthesis and finally smooth muscle contraction, followed. Most reports, such as that of Cosentino and coworkers [54] coincided in various aspects: a) the endothelial cell, when activated with acetylcholine would generate oxygen radicals which would in turn activate a cyclooxygenase that oversynthesizes all prostaglandins. b) Neither TXA 2 nor PGI 2 seemed to be the prostaglandins responsible. c) Most papers concurred in that TXA 2 receptor blockade on the smooth muscle cell reverted the contractile process and finally, d) the whole process, although present in healthy vessels, is exacerbated in hypertension. The problem of the sequence of events taking place from the initial acetylcholine activation with an intracellular calcium increase to the final contraction of the vessel was resumed a few years ago using state-of-the-art methodology. By means of intracellular imaging, it was demonstrated that cyclooxygenase activation occurs upstream of the generation of oxygen radicals [55] . One thing that was surprising in this report is that the traditional sequence of events (oxygen radical generation followed by cyclooxygenase activation) was inverted. A more recent report, elegantly resolves the debate on the order of events by showing the existence of a feedback loop between reactive oxygen species and cyclooxygenase-2. Under this scheme, one modulates the other and vice versa [56] (Fig. 3) . As stated before, the research on prostaglandins as EDCFs continued in parallel with the superoxide topic, and often both coincided in the same paper. For instance, a 1990 paper insisted in that oxygen-derived free radicals might be EDCFs and would cause contraction by stimulation of TXA 2 /PGH 2 receptors [57] . The latter was also found by Kato and others [58] .
A breakthrough in the EDCF topic took place with the publication featuring "The Janus face of prostacyclin" [59] . This referred to the double role of this, traditionally regarded vasodilator prostaglandin [23, 60] which was then proposed as one of the EDCFs together with other prostaglandins. This was not the first time this vasodilatory prostaglandin had been attributed vasoconstrictive properties [61] or even proposed as the chemical underlying EDCF [62] . What the Janus face paper introduced to the scientific community was the notion that all tested prostaglandins, including PGI 2 , elicit endothelium-dependent contractions by converging on TXA 2 receptors on the smooth muscle cell (Fig. 3 ). This happens in healthy, but most especially in hypertensive arteries and explains why many papers that appeared during the previous decade had persistently found that cyclooxygenase inhibition or TXA 2 receptor blockade, but not TXA 2 synthase inhibition, curtailed the endothelium-dependent contractions [50, 57, 58, 63] .
Endothelium-derived hyperpolarizing factor
During the progress of EDRF/EDCF investigation, some researchers realized that two facts did not fit in the endothelium-smooth muscle axis that had already been established. One was the observation that endothelium-dependent relaxation relied on three rather than two systems. Thus, EDRF and prostacyclin could not explain all the relaxing phenomena [64] . The second fact was the finding that the vasodilation elicited by acetylcholine could be detected, not only on the adjacent smooth muscle cells, but also along the arterial wall at a distance that exceeded the range of a mere paracrine effect [65] . To sort out this problem, the possibility that the endothelium causes electrical changes in the nearby smooth muscle cells was considered. The relationship between endothelial activity and myocyte hyperporization/relaxation was instinctively connected to the existence of released endothelium-derived hyperpolarizing substances, probably because of the enormous influence the EDRF milestone had on the scientific community [6] . Before Furchgott's discovery there was a confusion of reports in which acetylcholine caused either depolarization or hyperpolarization associated with either vasoconstriction or vasodilation of smooth muscle cells. Several examples were referenced by Bolton [66] . In the light of the recently known role of endothelial cells, Gordon and Martin studied in 1983 the effects of vasodilators on calcium-activated K + efflux from endothelial cells and its relationship with endothelium-dependent relaxation [67] . They found an increase in this efflux, which is the first step to induce a hyperpolarization, at least of the endothelial cell (Fig. 3 ). Although they did not assess membrane potentials, they did suggest that this cationic efflux might have some relationship with the relaxations. This was the prelude of the idea of K + as the EDHF that still took some years to be considered [68] . Shortly after the 1983 study, Bolton and colleagues went a step further showing that the inhibitory mechanical effect of carbachol, a stable cholinergic agonist similar to acetylcholine, on smooth muscle was associated to hyperpolarization of these cells. This turned into depolarization when the endothelium was removed. They were the first to mention the possibility of the existence of a factor released by endothelial cells causing hyperpolarization of the vessel wall [66] . With all this knowledge in mind, and that of their forthcoming publications, Weston and others introduced to the scientific public the term endothelium-derived hyperpolarizing factor or its acronym, EDHF [69] . This took place in 1988, a very productive year for EDHF. For example, this year Chen and others demonstrated the existence of a hyperpolarizing substance, distinct from EDRF, released upon acetylcholine stimulation. Using a K + efflux marker, concluded that this substance causes myocyte hyperpolarization by opening K + channels on the smooth muscle cell [70] (Fig. 3) . Next, Olesen and others also checked membrane potentials, but not in the myocyte but in endothelial cells, and demonstrated the existence of acetylcholine-activated (receptoroperated) channels on these cells. They showed that cholinergic stimulation causes hyperpolarization of the endothelial membrane and suggested that this endothelial hyperpolarization somehow would trigger the characteristic events of endothelium-dependent vasodilator responses [71] . The real link between endothelial hyperpolarization and myocyte hyperpolarization could not be understood until much later [68] . Finally, during this year of 1988, Félétou and Vanhoutte bioassayed the hyperpolarizing substances and provided the first evidence of the diffusible properties of EDHF [72] .
From then on, a quest aimed to find out the chemical nature of the EDHF(s) begun. By this time, EDRF had been already identified as NO, so this was the first proposed molecule. NO was initially ruled out [73] , but later reconsidered by Tare and others proving that NO blockers reduce acetylcholine-elicited hyperpolarization in some arteries [74] . Sometime later, these researchers demonstrated that not only NO, but also prostacyclin, exhibit hyperpolarizing abilities (Fig. 3) . Their proposal was that both of them contribute to the electrical phenomenon but without precluding the existence of a major EDHF [75] . Other candidates on the line were hydrogen peroxide and epoxyeicosatrienoic acids (EETs). Initial evidence showed that the oxygen-derived species, hydrogen peroxide, exhibits hyperpolarizing properties on myocytes but failed to pass the catalase test (forced conversion of hydrogen peroxide into water by this enzyme should inhibit endothelium-dependent hyperpolarization) [76] . However, Matoba and colleagues, nearly a decade later, succeeded in this aspect and presented hydrogen peroxide as a firm candidate for EDHF in a sequence of papers, the first of which was published in 2000 [77] (Fig. 3 ). Another possible EDHF was proposed in 1994. Hecker and others, on the basis of myographical evidences, suggested that the cytochrome P450 derivatives, EETs act as EDHFs [78] . A subsequent report that included the assessment of membrane potential changes confirmed Hecker's proposal [79] ( Fig. 3) . A large number of possible substances with endotheliumdependent hyperpolarizing properties has been suggested over the years and the whole coverage exceeds this revision. There are good reviews on this specific topic, for example, ref. [80] .
In 1998 Edwards and coworkers [68] picked up the thread of the work on endothelial K + efflux initiated by Gordon and Martin [67] and followed by Olesen's analyses of endothelial membrane potentials [71] . They showed that hyperpolarization of smooth muscle cells might be caused by endothelium-derived K + and performed a complete study of the endothelial channel source of this cation and the sites of action on the myocytes. Specifically, they confirmed the existence of a K + efflux from endothelial cells upon cholinergic activation via endothelial calcium-dependent K + channels. They also demonstrated that this ionized potassium present in the extracellular space acts as the EDHF by activating inwardly rectifying K + channels and a Na + /K + -ATPase of the smooth muscle cell membrane. In Edward's model, acetylcholine stimulation involves not only, the hyperpolarization of smooth muscle, but also the hyperpolarization of the endothelium (Fig. 3) . This simple idea of ionized potassium being an EDHF strongly reminds the well known textbook concept of local blood flow regulation, in which K + along with other metabolites cause local vasodilation. Indeed, the notion that potassium in low concentrations is a vasodilator can be dated back as early as 1938 [81] .
With all the mentioned EDHF possibilities, the problem of the third vasodilating factor we started with [64] had been addressed. However, the "remote" acetylcholine vascular relaxation described by Segal and Duling [65] , did not have a satisfactory answer if one counts only with the concept of hyperpolarization of adjacent cells. The only apparent way to solve the obstacle was to contemplate the possibility that this change in membrane potential, either of the endothelial cell or the myocyte, could be electrotonically transmitted to neighbouring cells. This is only possible if cell membranes join together in low resistance discrete locations called gap junctions. In the case of endothelial to myocyte junctions, the structural basis involves the approach of smooth muscle cell membranes towards those of endothelial cells. This was first described by Thoma in the early twenties who claimed to have observed cytoplasmic protrusions passing through fenestrae of elastic lamina which apparently contacted smooth muscle cells [82] . The advent of electron microscopy imaging in the fifties confirmed these pioneering observations [83] and a decade later Rhodin, with improved electron microscopy images observed in great detail these protrusions which he named "myoendothelial junctions". He also suggested that myoendothelial junctions may serve as a rapid communicating pathway between circulating hormones and vascular smooth muscle via endothelial cells: ". . .It would therefore be quite advantageous if some endothelial cells could serve as receptors [of humoral transmitter substances] which initiate the depolarization of the smooth muscle membrane. . .". Thus, Rhodin anticipated a functional role for these junctions [13] . Gap junctions are present in numerous cell types and have been detected between adjacent endothelial cells [84] and adjacent arterial smooth muscle cells [85] . The mere approach of two membranes does not imply the existence of a low resistance electrotonic connection. Gap junctions exhibit a characteristic pentalaminar pattern in electron microscope plates. Thus, bridges connecting endothelium and myocytes can only qualify as an authentic myoendothelial gap junction when this pattern is observed. In the case of myoendothelial connections, his was first described by Spagnoli and coworkers [86] .
The ultrastructure of gap junctions involves the docking of two membrane channels, each formed by six proteins. These were first characterized in 1974 by Goodenough who resolved naming then "connexins" [87] , inspired by the name "nexus", formerly given to gap junctions before this term was generally utilized [88] . A variety of connexins have been described over the years. Blood vessels (intima and/or media) specifically express connexins 43 [89] , 40 [90] , 37 [91] and 45 [92] (chronologically ordered as described, citations refer to the first description published). In 2006, Haddock and colleagues localized, by means of high resolution immunohistochemistry, connexins 37 and 40 to myoendothelial gap junctions in brain small vessels [93] .
The electrotonical transmition of hyperpolarization from cell to cell along the arterial wall was explored in profound detail by Segal and Duling's group during the years following their acetylcholine report [65] . The whole picture was beautifully reviewed by Segal in recent times [94] . Therefore, the problem of transmission was solved. Moreover, it was an incentive for some to go further by suggesting that, with functional myoendothelial gap junctions present, perhaps the existence of a diffusible factor (EDHF) was not necessary after all. For example, Chaytor and coworkers strongly highlighted the role of these membrane structures in endotheliumdependent relaxations [95] . Actually, these junction-transmitted relaxations have been referred to as "EDHF-type" [96] , for their strong resemblance to those mediated by the released factor, and the term EDH, rather than EDHF, is currently recommended [97] . In any case, these forms of endothelium-dependent relaxations, reliant on myoendothelial gap junctions are not, stricto sensu, within the scope of the title "paracrine control" of this review. Fig. 4 summarizes the electrical, paracrinal and mechanical phenomena using tracings from different sources [68, 98] and considering endothelial K + efflux as an example of an EDHF released from endothelial cells upon acetylcholine stimulation.
Search for the chemical nature of EDRF. Nitrovasodilators and cyclic GMP. The link EDRF-NO
Most of the period dedicated to EDCF and EDHF research was also devoted to try to unveil the chemical nature of EDRF. Actually, Furchgott's 1980 report included also a systematic study of most of the possible candidates for EDRF (ruling out cyclooxygenase-dependent products and specifically prostacyclin, bradykinin, adenosine, cAMP and cGMP) and part of the arachidonic acid/lipoxygenase line mentioned above [6] . The research on the molecule responsible for endothelium-dependent relaxations was especially focused on the possibility that EDRF could be a lipoxygenase product of arachidonic acid [99] [100] [101] [102] . By the mid-eighties this hypothesis had definitely reached a dead-end. There was another line of evidence that, looking at it from the perspective we have now, appears rather obvious, but it took years to be considered. This was the line of nitrovasodilators and guanylate cyclase that commenced a decade earlier.
In the mid-seventies various groups were working on cyclic nucleotides, especially the recently discovered cyclic GMP (cGMP) [103] . In the process of characterization of the soluble and particulate fractions of guanylate cyclase (the enzyme that synthesizes cGMP from GTP) a number of chemicals were used. Among these, Murad's group found that nitrogen compounds, such as azide (NaN 3 ) or nitrite (NO 2 Na) activated guanylate cyclase [103] . Other nitrocompounds were also reported to activate the formation of cGMP, such as nitroglycerin [104] and nitrosamines [105] . What attracted Murad's attention was that these nitrogen-bearing molecules acted on guanylate cyclase in a hormone-like fashion. In the course of this research, his group enlarged the variety of nitrogen compounds that activated guanylate cyclase [106] and discovered that all these compounds yielded nitric oxide (NO) [106] which strongly activated guanylate cyclase and generated cGMP [106, 107] . Some of these nitrocompounds were drugs known for more than a century for their anti-anginal [108] and vasodilatory properties [109] . Actually, and in parallel with the biochemical research, the abilities of these compounds to relax various smooth muscles and its relationship with cGMP was also being investigated [110] [111] [112] . Indeed, it was then when the term "nitrovasodilator" was introduced by Murad himself to refer to the NO-generating drugs that elicited vasodilation [113] . By the end of the decade, the biochemistry of guanylate cyclase activation by NO and nitrosocompounds and its connection with smooth muscle relaxation was quite well characterized. However, the link of NO with hormones, sought by Murad and the biological significance of the relationship between NO and guanylate cyclase was still an absolute enigma as admitted by himself [114] .
During the search for the chemical identity of EDRF over the early eighties, biochemical and physiological coincidences between the properties of NO and EDRF were being continuously reported. Even before the existence of EDRF was known, it was noticed that carbachol, an agonist similar to acetylcholine, increased the tissue levels of cGMP [104] . Once in the context of EDRF research, it was reported that this transferable factor, as stimulated by acetylcholine, is capable of increasing the release of cGMP from arterial strips [115] . Indeed, Murad forwarded the hypothesis that the effects of EDRF are mediated by cGMP [116] . A year later, Ignarro reported that the effects of both, nitrovasodilators and EDRF on vascular relaxation and cGMP accumulation was antagonized by the inhibitor of guanylate cyclase, methylene blue [117] . Shortly later, the same was published for hemoglobin [118] . In the subsequent year, three suggestive papers shed light on the reason why the lipoxygenase hypothesis for EDRF was being so confounding. Two of them demonstrated that superoxide anions destroy EDRF [119, 120] . The other, directly ascribed the effects of lipoxygenase inhibitors to their redox properties rather than to any specific action on EDRF [121] . Coincidences between the biological actions of nitrovasodilators and those of EDRF, such as that both inhibit platelet aggregation [122, 123] , were being reported. Perhaps the most peculiar coincidence was Rapoport's finding that both, nitrovasodilators and EDRF, induce desensitization associated with a decrease in the formation of cGMP [124] . More precisely, EDRF (as stimulated by acetylcholine) elicited lesser relaxing effects after exposure to a nitrovasodilator. This meant that EDRF was desensitized by the nitrovasodilator and thus, necessarily held a common underlying mechanism.
It is remarkable that with all this mass of evidence, the scientific community was so reluctant to admit that EDRF was a nitrovasodilator. An example of this reluctance is that even the nucleotide cGMP was proposed as a candidate for EDRF's chemical nature [115] [125] . The reason why it took so long to perform the experiments that proved this relationship was probably that never before a molecule of such a small molecular weight had been regarded as a biological mediator, and even less when the putative mediator, NO, is a toxic gas as well.
Palmer and coworkers first reported that NO accounts for the biological activity of EDRF in 1987 [126] . Shortly later, a paper by Ignarro [127] and a bookchapter by Khan and Furchgott [128] , showing fundamentally the same, appeared in the press. Actually, Ignarro's group published numerous papers on the chemical nature of EDRF as NO nearly at the same time [127, [129] [130] [131] , thus indicating that the three groups were concomitantly working in the same topic (Fig. 3) . [88] . Acetylcholine was administered by microiontophoresis on muscle feed arteries. K + concentration, used in this case to illustrate an example of an EDHF, was measured in the myo-endothelial space by Edwards and coworkers [68] (modified). Acetylcholine was administered in a regular manner on hepatic resistance arteries.
The NO pathway
The publication of the NO identity of EDRF by Moncada's team [126] came from a group that had not worked before in the field of nitrovasodilators but with prostaglandins, as stated in previous sections. Moncada's group took advantage of their expertise in the bioassay cascade preparation [4] , which was powerfully reinforced with endothelial cells cultured on beads. They had to develop new specific methodology to assess NO release from endothelial cells. Curiously, this methodology came from the use of nitrite sensors based on chemiluminescence adapted from the motor industry. All this finally allowed proving that the pharmacological properties of EDRF and NO are indistinguishable. This was nicely reviewed in more recent years [60] . Despite the group was a newcomer in the nitrovasodilator field, rapidly took the lead, especially unravelling the biochemical pathway of NO synthesis and the origin of NO as synthesized from L-arginine. The discovery served as a strong incentive to boost the research in the NO field as seen by the dramatic rise in publications over the following years (Fig. 5) . Evidence was sufficient to recognize NO as the endothelial endogenous nitrovasodilator, in the sense Murad gave to this term [113] . This, when specifically referring to the vessel wall [132] but, in general, NO was regarded as a ubiquitous mediator of cell communication [133] .
Especially relevant to NO exploration was the research on the synthesis of NO from L-arginine that led to the establishment of the NO pathway. This discovery had a long history behind of various reports on scientific topics unrelated with vascular biology and in some instances unrelated between each other. It just needed somebody to put them together and link them with EDRF. The sequence of reports that led to the l-arginine-NO pathway started up with a topic initially unrelated with this pathway: nitrate, nitrosamines and cancer. There was a long lasting debate on whether nitrate (NO 3 − ) is produced endogenously by mammalian cells and if so, how. Measurements performed early last century indicated that urinary nitrate had to be synthesized within the body albeit no pathway was known for the synthesis of this anion [134] . The topic was revisited in the late seventies by scientists concerned about the possibility that the exposure to nitrate could yield to the fearsome compound, nitrosamine, clearly related to stomach cancer. Initially it was hypothesized that this endogenously formed nitrate was the result of the metabolism of the intestinal flora [135] , but experiments on germ-free rats showed that, definitely, mammals were able to make themselves nitrate [136] .
The following year, a clinical paper appeared reporting the existence of children with methaemoglobinemia, a condition caused, among other factors, by high environmental exposure to nitrites or nitrates [137] . These children exhibited a very high concentration of plasma nitrate and severe methaemoglobinemia. These observations would have nothing to do with the present topic on the NO pathway except for the fact that those children had never been exposed to water or food-containing nitrates. What all those infants had in common was that all of them suffered an acute diarrhoea. The possibility that a bacterial gastroenteritis was behind the appearance of this increased endogenously-synthesized nitrate concentration prompted Tannenbaum's group to check this point in animals challenged with bacterial endotoxin. The result was a dramatic rise in nitrate production [138] . Because this appeared to be an immune reaction, macrophages were the first candidate cells to be examined. Stuehr and Marletta performed the experiment in these cells and found a sharp rise in nitrate release taking place when cultured macrophages were treated with endotoxin [139] . At the same time another group was carrying out a line of research, which was also related with the immune system. Hibbs, the senior of this group, had been interested in the interaction of macrophages with tumour cells and the biochemistry of the activated macrophage mechanisms of cytotoxicity. It had already been observed a long time before that arginine inhibited the growth of tumours [140] . Aware of this, Hibbs, during the course of the biochemical studies, observed that macrophages failed to become active upon immunological stimulation if no amino acids were present, but fully able to attack neoplastic cells if l-arginine, but not the dextrorotary form, was present in the medium [141] . Intrigued with this finding, the group went on studying in depth the biochemistry involved. In this initial report, they found that methylated analogues of l-arginine inhibited macrophage induction. Further research on the arginine issue, and already knowing about the nitrate release from macrophages upon endotoxin stimulation [139] , led the group to the proposal that the origin of that nitrate could be l-arginine [142] . In this paper [142] , Hibbs demonstrated that l-arginine was oxidized to nitrite and l-citrulline, and proposed a preliminary biochemical pathway, which he recognized, had never been seen before in living cells [142] . Still, these results did not link l-arginine with NO yet.
A piece of evidence that led to the association between nitrate, l-arginine and EDRF was disclosed because after the discovery of EDRF as NO, many groups initiated a research campaign looking for NO synthesis, not only in the endothelium, which was the starting point, but also elsewhere in different organs and systems. One of these was the central nervous system. Inevitably, this search led to a report published some years before by Deguchi and coworkers on the activation of guanylate cyclase in brain cells [143] . By the year this research was being carried out, Deguchi was aware that nitroso-compounds could activate guanylate cyclase, but what they were trying to find was an endogenous substance able to activate this enzyme. They had a strong background in fine chemistry, which they utilized. The result was that they were able to specifically purify L-arginine from the brain extract. They even compared the activation pattern of guanylate cyclase with that of nitrosocompounds and noticed the similarities. They also pointed out the chemical resemblance of L-arginine and some nitroso-compounds [143] . They did not know about NO or any synthesizing pathway, but the data they had was remarkably close to it.
It can be seen that all the reports we have mentioned were published over a very long period of time, they were apparently unrelated between each other and published in journals devoted to different topics. Specifically selecting the right papers at a time when computer search engines were practically inexistent and putting them together in the right order appears today like looking for a needle in a haystack. However, this seemed to be no handicap and it did not take long after the discovery of EDRF's chemical nature to identify L-arginine as the precursor of NO. The first report came from Moncada's lab [144] who had focused part of his research in the brain NO synthase [145] and noticed Deguchi's report. At the same time, they had a long time expertise in the immunology/inflammation area [20, 23] that helped joining together the brain guanylate cyclase report with the different findings published earlier on endogenous nitrates and l-arginine dependency of macrophage activation. Still, and once again, the same idea was pursued independently by other groups who published shortly after. One group confirming l-arginine as the precursor of EDRF [146] and another demonstrating that NO is the intermediate molecule between L-arginine and nitrate [147] previously described in macrophages [142] . Fig. 6 summarizes the three main lines of research that yielded to the first step of the l-arginine to NO biochemical pathway.
Quickly, l-arginine methylated analogues, already used by Hibbs [141] , were tested on endothelium-dependent relaxations to inhibit NO synthesis [148] and the first partial characterization of the enzyme, which was later named endothelial NO synthase, was performed [149] (Fig. 3) . A major implication for research of the availability of these analogues was the possibility to leap from the single vessel [148] to a whole organ [150] and finally to the entire individual [151] . These two publications proved that NO, basally released, has a permanent vasodilatory action that sets perfusion pressure [150] and even the entire blood pressure [151] to a physiological point that is very well below the pressure that would exist without NO. These observations led to the notion of the vascular system as a conductance, rather than a resistance system and are clearly explained in a review published later on by Moncada [60] .
All these advances ignited a rise in NO research that peaked in 1992 (Fig. 5) . NO synthases were found in numerous tissues besides the vessel wall (for review see ref. [152] ) and the 1991 revision published in Pharmacological Reviews [153] became the highest cited paper ever in vascular pharmacology (12096 citations in a recent search and followed by Furchgott's 1980 paper with 6569 citations). The following year, NO was awarded the "Molecule of the Year 1992" [154] , and finally, the 1998 Nobel Prize in Physiology or Medicine was awarded for the discoveries concerning NO as a signalling molecule in the cardiovascular system.
After 1992, research in the NO field was vertiginous. To mention just a couple of examples on how the newly incorporated biochemical route of l-arginine affected the map of biochemistry known by that time, it is worth making an allusion to endothelial arginase and endogenous arginine derivatives. Before the l-arginine-NO pathway was incorporated to the textbooks, the hepatic urea cycle was the major known destiny of arginine via the arginase reaction. It was eventually noticed that endothelial cells possess arginase activity and produce urea [155] . It was suggested [156] , and more recently proven [157] , that the role of endothelial arginase is to regulate the substrate provision for endothelial NO synthase and, thus, NO-dependent relaxation. Another remarkable aftereffect of the newly acquired knowledge in arginine biochemistry was the recovery of very old reports on the presence of endogenous arginine derivatives in the urine [158] . This was of enormous interest once known that l-arginine analogues inhibit NO synthesis [148] because it represented the possibility that NO synthase inhibitors were, not only drugs, but physiological actors of the l-arginine-NO pathway, the so-called endogenous inhibitors of NO synthase. The first of these, asymmetrical dimethylarginine (ADMA), was detected by Vallance and colleagues in human urine [159] and later in human endothelial cells [160] . These two natural controllers of the NO pathway, endothelial arginase and ADMA, have been extensively studied from a cardiovascular disease point of view that exceeds the limits of our review.
At this time point, the 3 major endothelium-derived paracrine vasoactive substances (EDRFs, EDCFs and EDHFs) were perfectly catalogued (Fig. 3) . One aspect that tempted vascular physiologists was to compare each of them in different vascular beds, most particularly, in conductance versus resistance vessels. Furchgott verified from the very beggining of his research that EDRF release takes place, not only in large conductance vessels where he made the discovery [6] , but also in arteries small enough to control regional blood flow [161] . Once NO synthase inhibitors became available, it did not take long to realize that these inhibitors were more efficient in large compared to smaller arteries [162] , something that was ascribed to a differential role of NO versus EDHF in large and small arteries, where the importance of EDHF increases as the vessel's calibre diminishes [163] . This notion confirmed the earlier electrophysiologist's finding that microvascular endothelial cells hyperpolarize upon agonist stimulation more efficiently than the macrovascular do [164] . In practice, however, both NO and EDHF have demonstrated to be key elements of the circulatory control in vivo [151, 165] .
Adventitia and periadventitial adipose tissue
It can be noticed that, so far, the leading character in the paracrine control of the vessel's function has been exclusively attributed to the endothelium, with NO at the front as the canonical vasodilator. The abluminal layer, the adventitia, had been generally overlooked. This scenario is now changing. While the textbook paradigm holds that the vascular wall consists of tunicae intima, media and adventitia, a forth layer, the tunica adiposa has been recently claimed [166, 167] on the basis of the clear influence that periadventitial adipose tissue has on vascular function. Thus, perivascular adipose tissue (PVAT), up to now regarded as "extravascular", is being increasingly considered an "intravascular" structure. While some talk about four layers [166] [167] [168] , others prefer to consider the existence of three, and divide the third one in "adventitial compacta" and "adventitial fat" or PVAT [169] . The "compacta" is the classical adventitia and is made mostly by fibroblasts, but also macrophages, dendritic cells, progenitor cells, vasa vasorum endothelial cells, pericytes and nerve endings [170] . The tunica adiposa or PVAT is mostly formed by white or brown adipocytes (depending on the depot), but also by the so-called stromal vascular fraction, which includes preadipocytes, fibroblasts, mesenchymal stem cells, lymphocytes, macrophages, nerve endings and vasa vasorum endothelial cells [171] . As for the nerve endings, these are loose varicose sympathetic or parasympathetic autonomous fibres. The two may innervate smooth muscle cells but adipocytes are mainly sympathetically innervated [172] . Whether adipocytes receive parasympathetic innervation is a matter of intense debate [173, 174] . To avoid confusions between both layers of the adventitia, in this review we will simply name "adventitia" to the tunica adventitia stricto sensu and "PVAT" to the new tunica adiposa or outermost limits of the vessel.
The reason why the adventitia has received little pharmacological attention as compared to the endothelium relies on the technical difficulties to remove it properly [175] so as to investigate its roles in a similar fashion as it was done with the endothelium. In contrast, PVAT is fairly easy to remove and, paradoxically, this is the reason why it took so long to notice its vasoactive roles. In the large majority of myographic studies perivascular fat is removed on a routine basis. This practice is based on the assumption that PVAT is a extraneous tissue and, worse, may impede the diffusion of vasoactive substances to the "authentic" vascular tissue, as explained by researchers in the PVAT field [176] .
The paracrine role of the adventitia
If the endothelium was once considered a "tapestry", the adventitia has been generally regarded as a mere connective support of the vessel with no active role to be sought in. Possibly the first study to introduce an active role on vascular function was the discovery in 1995 of a powerful superoxide-generating system within the adventitia [10] . However, prior to this year, few scattered studies revealed some abilities of adventitial cells with regard to various vasoactive substances such as prostacyclin [26] , histamine [177] , angiotensin converting enzyme [178] , traces of angiotensinogen [179] or serotonin [180] . Shortly before the adventitial superoxide preliminary finding [10] , a suggestive study was published on a possible functional activity of adventitia, in this case as a barrier specifically arranged against endothelial NO [181] . Pagano's study on adventitial superoxide generation was followed by a series of reports that increasingly clarified this topic: the NADPH oxidase, responsible for superoxide generation, was pinpointed to the adventitial fibroblasts [182] and the functional barrier described by Steinhorn and others was imputed to this superoxide for its role in inactivating NO [183] . In 1999, it was stated that adventitial superoxide does play a paracrine role [184] . Therefore, the adventitial fibroblast began to qualify as a paracrine cell, at least in what vasomotion is concerned. In the meanwhile, it was reported that the adventitia is able to generate NO, but only when challenged with endotoxin [185, 186] . It must be remarked that fibroblasts seem to be unable to produce NO without prior induction [187] .
The technical difficulties to obtain vascular preparations devoid of adventitial cells have been overcome by various means. One is a curious set-up in which the artery ring is pharmacologically assessed inside-out with the adventitia facings outwards [183] or combining physical removal with collagenase treatment [188] . This latter method permitted to observe that the adventitial layer allows for stronger smooth muscle contractions (Fig. 7D) and smaller endothelium-dependent relaxations, thus clearly establishing a role for the adventitial layer in the regulation of the vascular wall [188] . The impact the adventitia has on endothelial function was again ascribed to superoxide's action [189] and more recently to hydrogen peroxide [190] . Additionally, it has been demonstrated that fibroblasts produce endothelin-1, thus including this peptide to the short list of adventitial paracrine vasoactive substances [191] .
The paracrine role of PVAT
Before today's interest in PVAT became commonplace, adipocytes were already known to synthesize and release hormones related to energy homeostasis and, together with macrophages, operate as immune cells. This, due to their ability to produce cytokines, in this case, adipocytokines, which are largely the same ones as those produced by genuine immune cells [192] .
The novelty actually was the suggestive possibility that adipocytes acted as paracrine cells to the vessel wall by releasing transferable substances with vasomotor abilities. Obviously, this is only possible when adipose tissue is close to the artery, a circumstance that only happens in the case of adventitial fat, that is, PVAT. In this sense, adipocytes would operate in conjunction with intimal endothelial cells. This idea was materialized by Löhn and colleagues who first demonstrated that the adipose tissue surrounding the adventitia is able to release a transferable factor that affects vascular tone. In 2002 they published the existence of a diffusible factor derived from PVAT, which received the evocative name of ADRF, the acronym of "adventitium-derived relaxing factor" [9] . In a following paper of the same group, they decided that the "A" should stand for adipocyte instead of adventitium [193] and from then on, both names have been used indistinctly, with the common acronym of ADRF. In these first reports, they demonstrated that dose-response curves to various vasoconstrictors (phenylephrine, angiotensin II and serotonin) were systematically smaller when the arterial segment was tested without dissecting off the perivascular fat (Fig. 7C) . They also showed that Krebs buffer collected from an artery incubated also in these conditions, i.e. with PVAT, was able to elicit a relaxing response when added to a segment fully dissected and precontracted with one of the vasoconstrictors [9, 193] .
In the following lines we will review the historic progress of this idea, which has yielded to a new vision of the vessel, both functional (perivascular adipocyte working in conjunction with the endothelial cell) and morphological (the recent inclusion of PVAT as the fourth layer of the vessel's histology) [166] [167] [168] [169] . Even pathophysiological: a "perivascular adipose tissue dysfunction" has been proposed [194] . 1 Furthermore, the ultrasonographic measurement of the adventitia/media thickness (which includes PVAT) has been proposed as an alternative to the traditional intima/media thickness to predict cardiovascular risk [195] .
Although a great deal of enthusiasm has been placed on PVAT as an alternative paracrine source of the vessel wall, before going on, it is important to emphazise that there are major differences between the endothelial tissue and PVAT. Aside from the obvious fact that endothelial cells are directly subjected to the influence of the blood stream, the first dissimilarity between both tissues is that intimal endothelial cells are (or should be) always present in whatever kind of vessel and in the entire circulation. In contrast, PVAT is absent in numerous vessels. Large conduit arteries and veins are generally surrounded by the adipose tissue they run through, but this is normally left behind once they penetrate into an organ. Cerebral blood vessels typically lack PVAT. Additionally, if we consider that the whole pulmonary and systemic capillaries (except those that irrigate fat depots) are completely devoid of adipose tissue, this relegates PVAT to a relatively small proportion of the circulatory system. A second difference is that, while PVAT is comprised by numerous cell types (see classification in ref. 171) , the tunica intima is, in physiological conditions, made exclusively by endothelial cells and some subendothelial fibroblasts. On the other hand, both tissues have things in common. For example, PVAT has large phenotypic differences depending on the specific location of a given adipose depot [196] [197] [198] [199] and this confers differences in the ability to control the underlying vessel [200] . This reminds very much the well know heterogeneity the endothelium exhibits in the kind of 1 A dysfunctional PVAT has hypertrophied, lipotoxic adipocytes, a condition generally occurring in visceral adipose tissue upon a lipid overflow due to the positive energy balance of obesity. These visceral adipocytes exhibit an abnormal pattern of adipokine secretion. The extrapolation of this condition to the adventitial adipocytes makes PVAT a dysfunctional one in that there is an excess in adipocytokine secretion and an undesirable release of vasoactive adipokines both with unhealthy consequences for vascular function. (A and B) , 2) the anticontractile effect of PVAT (C) and the procontractile effect of adventitia. Observe that Soltis and Cassis did not find any effect of PVAT on phenylephrine contractions, an observation attributed to the lack of recaption by PVAT's nerve endings (B). This recaption does take place when the vessel is challenged with noradrenaline (A), but not with phenylephrine (B). Löhn and colleagues were able to demonstrate the release of an anticontractile substance from PVAT in response to phenylephrine stimulation (C). In sharp contrast with the tunica adiposa or PVAT (C), the tunica adventitia exhibits procontractile properties in the same artery [188] as well as carotid artery (D). Graphs reconstructed from ref. [8] (A and B) , [9] (C), and [187] (D). + = tissue present. − = tissue removed. substances released depending on the vascular region [41] . Another property shared with endothelial cells is the ability to synthesize prostaglandins and NO. General adipose tissue releases NO [201] and prostaglandins [202] . PVAT in particular, also releases these two substances [203, 204] .
The first description of the modulatory action of perivascular fat on vascular contractility was reported eleven years before Löhn's publication, by Soltis and Cassis [8] . This work has been sometimes misinterpreted as the first postulator of a prorelaxing role of PVAT. Actually, what these researchers describe is PVAT as the physical carrier of sympathetic recaption by these nerve endings, which are present both in the adventitia and in PVAT. Soltis and Cassis observed an abolishment of noradrenaline-mediated contractions (electric or tyramine stimulation) in the absence of PVAT and a decrease in the sensitivity to noradrenaline itself when aortic segments have an intact PVAT (Fig. 7A) . They elegantly demonstrated that this is caused by the uptake and removal of this particular catecholamine by adipose tissue and suggested that the nerve endings within PVAT recapt and eliminate noradrenaline present in the synaptic gap. This, understandably, ends up in a buffered effect of this effector, but they never stated that PVAT releases any sort of relaxing or anticontractile factor. In fact, they did demonstrate that the experiment worked only with noradrenaline, which underwent recaption, but not with phenylephrine or potassium, which did not (Fig. 7B) . It must be noted, however, that in addition to these observations, Soltis's paper anticipated in nearly two decades the possibility that angiotensin II of PVAT's adipocytic origin influences vascular tone [205] . This idea was also proposed in a previous work by the same group showing the presence of high levels of angiotensinogen mRNA in aortic PVAT [179] .
Identity and mechanism of action of PVAT's paracrine substances
Adipose tissue has progressively gained the category of endocrine gland in a similar fashion as the endothelium once had [7, 206] . The substances synthesized and released by adipocytes, collectively known as adipokines [207] , exceed the hundred in number [208] . Considering that adipocytes represent >60% of adipose tissue [209] and the enormous hormonal potential these cells possess, it is quite reasonable to assume that some adipokines, when released from adipocytes anatomically close to the vessel (within PVAT), reach the tunica media, or even the endothelium and the blood stream, and affect vascular function. This assumption inspired Yudkin and others to coin the term "vasocrine", referring specifically to the paracrine communication between PVAT and the artery it surrounds [210] . Amongst the catalogued adipokines, many exhibit vasoactive properties to some degree besides their main function. This text does not attempt to fully describe the vascular-related findings of each adipokine. Excellent reviews on this topic have been published, for example ref. 211 . Still, we can perform a rough classification of adipokines from the vascular physiologist's point of view, as follows: a) Vessel-targeted substances with uncertain chemical identity specifically studied in PVAT. b) Adipokines implicated in energy homeostasis. c) Classic vasoactive hormones with adipocytic origin. d) Adipocytokines or pro-inflammatory cytokines. e) Reactive oxygen species.
Vasoactive adipokines can be sorted as well considering whether the vasomotor action takes place directly on smooth muscle cells o via activation (or inhibition) of the release of endothelium-derived vasoactive substances. This aspect will be also taken into account. a) Vessel-targeted substances with uncertain chemical identity specifically studied in PVAT
The existence of these substances is known through experiments in which a physiological solution containing undissected [9] or dissected [212] PVAT of a particular artery is transferred to another artery devoid of PVAT that, in response, elicits a vasodilation. This kind of experiment proves that the adipokines in question are released by PVAT and are transferable. Presumably these adipokines are specifically released by PVAT and specifically targeted to the PVAT's surrounding artery, but whether other fat depots release adipokines with the same properties has never been studied. The chemical identity of the adipokine(s) is unclear but often proves to relax the vessel by hyperpolarization after opening potassium channels of different kinds on the smooth muscle cell. As explained before, when they were discovered, these substances were collectively named adventitium-or adipocyte-derived relaxing factors (ADRFs) [9, 193] . The presence of ADRF is frequently demonstrated in experiments in which a vessel is subjected to a concentration-response curve to a vasoconstrictor (Fig. 7C) and, thus, they are sometimes refered to as anti-contractile substances.
The initial reports on the discovery of ADRF already pointed out that the anti-contractile transferable substance is able to open K + ATP channels and this action is dependent on extracellullar calcium, tyrosine kinase and protein kinase A, while being endothelium-and perivascular nerve-independent [9, 213] . This was demonstrated in rat aorta. When other vascular beds were under study, different channels were found to be involved. K + V delayed rectifier channels were proposed in the rat mesenteric artery [193] , while K + Ca channels were the target of the very first study on ADRF carried out in human arteries. This was performed by Gao and colleagues [214] . Curiously, this group, when working on rat mesenteric arteries found that the presence of PVAT augmented, rather than diminish, contractions caused by electrical stimulation [215] . They argued that this is a specific phenomenon taking place in perivascular nerve endings within PVAT and this action would be mediated by superoxide anion produced by NAD(P)H oxidase [215] . In a review written later, Gao proposed to call perivascular adipocyte-derived constricting factor (PVCF) to substances of this kind so as to distinguish them from ADRF. More recently, this has also been refered to as "adipose-derived contracting factor" (ADCF) [216] . Gao suggested that not only superoxide, but other substances could act as PVCFs, thus PVAT would elicit a dual, anticontractile and pro-contractile action on the vessel it surrounds [217] . Later research demonstrating that the substance released by adipocytes upon electrical stimulation is angiotensin II [205] , confirmed Gao's suggestion of a PVCF different from superoxide. In the mean time, Gao kept working on the influence of PVAT in other vascular beds. His group reported that rat aortic PVAT releases a transferable factor that operates under two mechanisms.
One mechanism would be endothelium-independent but, unlike ADRF reported in 2002 which depended on potassium channel opening, they found it would be (or depended on) H 2 O 2 . Another mechanism would cause the opening of potassium channels but, in contrast to the initial report on rat aortic PVAT, this mechanism is endothelium-dependent and, in this case opens K + Ca , not K + ATP , channels [218] .
Although the existence of transferable factors from PVAT is indisputable, opinions on the identity and mechanism of action are heterogeneous. Löhn and Dubrovska initially discarded NO, prostaglandins and other mediators by using specific inhibitors [9, 213] . Possibly the first attempt to pinpoint a particular substance was that of Gao and coworkers with H 2 O 2 [218] . However, they did not propose a firm candidate until two years later showing that the identity of the factor responsible of the endothelium-dependent effects they detected is angiotensin 1-7 [219] . By the same year, another proposal was published: the gas H 2 S, via K + ATP channels [220] . Later, another group asevered that the fatty acid, palmitate is the ADRF acting through K + V channels [221] . Finally, adiponectin, which had been already ruled out as an ADRF [222] , came again into scene through two 2013 publications showing that adiponectin is an ADRF causing anticontractile effects by opening K + Ca channels [223, 224] . Whatever the nature of ADRF, potassium channel opening has been repeatedly shown as a mechanism underlying the action of this factor. The first to positively confirm that the anti-contractile effect is accompanied by a hyperpolarization of the smooth muscle cell membrane were Dubrovska and colleagues [213] . Years later, Weston and others proposed the acronym of adipocyte-derived hyperpolarizing factors (ADHFs) to refer to the anticontractile substances that relax the vessel's smooth muscle cell by means of membrane hyperpolarization [224] .
b) Adipokines implicated in energy homeostasis
These are proteins involved in energy balance, insulin resistance, diabetes or obesity which have shown influences on vascular function as well. This group includes leptin, adiponectin, chemerin, omentin, apelin, resistin and visfatin. Leptin is the major adipocyte-derived hormone involved in the control of food-intake homeostasis. Leptin was also the first adipokine reported to influence vascular function. The discovery that leptin receptors are present on endothelial cells [225] made the vascular wall a potential target of this hormone. This was originally noticed by Frühbeck who suggested that leptin induces the release of NO [226] . The paracrine actions of leptin on the vessel wall are not easy to establish on the basis of what has been published since reports on the vascular actions of this adipokine are conflicting. The earliest reports show that leptin elicits NO-dependent [227] and −independent [228] vasodilation, which is difficult to reconcile with the epidemiological data repeatedly showing that leptin is linked to the cardiovascular malfunctions of obesity (For review see ref. [211] ). Studies carried out specifically with PVAT have demonstrated that PVAT-derived leptin clearly causes endothelial dysfunction in the obese animal (not the control counterparts) [229] . However, numerous studies suggest the possibility that leptin could be an endothelium-dependent ADRF [230] [231] [232] . In this sense, leptin has been considered a paradoxical substance in that it causes NO-dependent vasodilation and, at the same time, its very presence impairs endothelium-dependent relaxations [233] .
Adiponectin is well known by cardiovascular epidemiologists as the adipokine that opposes leptin's actions [211] . An excess of this one and a shortage of adiponectin has been associated with the vascular undesirable effects of obesity [211] . Adiponectin has shown endothelial NO stimulating activity [234, 235] and NO-dependent vasodilating actions [236] . Such is the vasodilatory reputation of adiponectin that it has been proposed as the unidentified [224] substance behind ADRF [223, 224] . In sharp contrast to adiponectin, chemerin, has been shown to be a PVAT-derived adipokine with pro-contractile [237] as well as endothelium dysfunctioning [238] properties, operating possibly via NAD(P)H oxidase [239] . Visfatin of PVAT origin has shown no effects on contractility [240] but, in non-PVAT set ups, visfatin elicited strong endothelial function impairments [241] . Finally, omentin and resistin have not been tested in PVAT but it has been reported that resistin impairs endothelial function [242] and omentin causes mild endotheliumdependent relaxations [243] .
c) Classic vasoactive hormones with adipocytic origin
These are vasoactive endocrine or paracrine hormones generally known for being released from glands or tissues different from adipose tissue (e.g.: angiotensin II or NO) but were later demonstrated to have an adipocytic origin as well. The discovery that adipocytes are able to synthesize and release classic vasoactive hormones paralleled the progressively enlarging list of adipokines. To date, traditional vasoactive substances that happen to be adipokines at the same time are: NO, prostacyclin, prostaglandin E 2 , TXA 2 , endothelin-1, angiotensin II, aldosterone and noradrenaline. First reports on the synthesis and release of the vasoactive substance in question, either carried out using adipocytes from adipose tissue (AT) other than PVAT, or using PVAT itself, are the following: NO from AT [201] and NO from PVAT [203] . Prostacyclin from AT [244] and from PVAT [204] . Prostaglandin E 2 from AT [202] and from PVAT [245, 246] . TXA 2 from AT [247] and from PVAT [216, 245] . Endothelin-1 from AT [248] and from PVAT [245] . Angiotensin II, both from AT and from PVAT [249] . Aldosterone from AT [250] (no report on PVAT). Finally, noradrenaline from AT [251] and from PVAT [252] . It is remarkable that some of the reports are really old, such as the adipocytic synthesis of prostaglandins [202] , but not until recently these were recognized as PVAT-derived adipokines [204, 216, 245] . Also longstanding is the recognition that adipocytes are able to synthesize angiotensinogen [253] as well as the suspition that adipose tissue would be able to produce angiotensin II [8] . The fact that PVAT releases the same substances that were supposedly produced by the endothelium has numerous implications, mostly studied in the context of obesity, and exceed the capacity of the present review. As mere examples, notice the relevance that a PVAT of the visceral fat depot would have for the obese person when proven able to compete with the vascular endothelium for the release of major vasoconstrictors like endothelin-1 [248] or TXA 2 [216, 245] . Or the fact that adipocytes within PVAT releases angiotensin II towards the surrounding vessel, thus adding up to the same vasoconstrictor released from adrenal glands or elsewhere. The same can be said about aldosterone. Indeed, it is now recognized that the adipocyte is provided with the complete synthesizing machinery of the renin-angiotensin-aldosterone system [249, 250] .
Another remarkable fact of PVAT, although only one report in mice aortae exists, is that it is able to produce sufficient NO to relax an acetylcholine-stimulated deendothelialized artery [254] . If this is confirmed, it would imply that PVAT possesses much more than a casual ability to affect the vessel's function by substances that otherwise all adipocytes produce. PVAT would possess a role in the control of the vascular tone nearly as specific as that of the endothelium. That adipocytes are metabolically responsive to acetylcholine is known since the sixties [202] . It would be interesting to investigate the pathways linking muscarinic receptors and NO synthase and whether other classical endothelium-dependent vasodilators can stimulate PVAT to release NO. In relation to all this, it has been proposed that PVAT-derived NO would play a transitory adaptive role in the early stages of obesity [255] .
d) Adipocytokines or pro-inflammatory cytokines
Adipocytokines are cytokines synthesized and released by adipocytes [207] . These substances are normally produced in inflammatory conditions, induce the formation of NO by the inducible form of NOS [256] but impair endothelium-dependent relaxations [257] . Adipocytes within PVAT are also able to produce these substances. In fact, the PVAT fat store displays a particularly proinflammatory phenotype compared to the subcutaneous depot, and releases more adipocytokines [196] . This is true in a normal situation [196] , but is exacerbated in injurious conditions [258] . Therefore, and using the title of the first report on cytokines and endothelial function [257] , PVAT must have "an anti-EDRF effect". This intuitive idea has been proven in experiments performed in arteries studied with or without PVAT [259] and specifically related to tumor necrosis factor-␣ [260] . It must be emphasized, however, that not every report confirms that PVAT is a detereous tissue merely for having a basal adipocytokine releasing ability. For example, Rittig and others stated that PVAT causes no endothelial dysfunction [261] and various studies indicate that endothelium-dependent relaxations are not altered in vessels with a preserved PVAT as compared to vessels without PVAT [245, 262] . Rather, endothelial dysfunction is detected when this experiment is performed in obese animals [245, 262] . The obese, in turn, exhibit a loss in anticontractile function that can be improved with cytokine antagonists [263] .
e) Reactive oxygen species
Following a similar scheme as with other adipocyte-derived substances, production of reactive oxygen species was originally described in adipocytes many years before the concept of PVAT existed. In this case, it was H 2 O 2 released as a byproduct of adipocyte's glucose metabolism [264] . The first to link PVAT with free radicals were, as previously stated, Gao and coworkers with H 2 O 2 in the role of a vasodilator [218] and later, superoxide acting as a vasoconstrictor [215] . A recent study emphasizes the role of dismutation of procontractile mitochondrial superoxide into anticontractile H 2 O 2 , thus reconciling the conflict [265] . The increase in Table 2 Substances released by PVAT, which have shown to relax, contract or cause endothelial dysfunction of the surrounded vessel.
PVAT-derived relaxing adipokines
References PVAT-derived contracting adipokines or adipokines producing endothelial dysfunction References Unidentified [9, 193] superoxide production by PVAT has been linked to the vascular malfunctions of obesity such as failure of anti-contractile activity [263] and endothelial dysfunction [262] . Most authors coincide in that the superoxide-generating enzyme in PVAT is NAD(P)H oxidase [215, 266] . Many obesity papers tend to report together the excessive production of adipocytokines and oxygen radicals [262, 263] , but only Virdis and colleagues demonstrate a cause-effect relationship between tumor necrosis factor-␣ and reactive oxygen species production in PVAT [266] . Table 1 shows the principal milestones of PVAT research and discovery and Table 2 summarizes the substances released by PVAT which have shown to relax, contract or cause endothelial dysfunction of the surrounded vessel. For the sake of caution, substances are refered to as relaxing or contracting adipokines, rather than calling them ADRF or PVCF because the quoted reporting paper often does not do so, or simply states that the substance under test is a candidate for ADRF or PVCF to be considered.
Interactions between PVAT, smooth muscle and endothelium
The classic vision of the paracrine control of the vessel wall implicated an inside-to-outside signaling via prostacyclin, NO, EDHF or EDCFs. The irruption of PVAT and its ability to signal inwards has complicated the scenario. A possible crosstalk between endothelial cells and adipocytes was actually proposed very much earlier than PVAT was described [267] . In addition, a review was published in the early nineties defending the idea that adipocytes are the source of arachidonic acid for endothelial prostaglandin synthesis and, therefore, that endothelial prostaglandin release requires the cooperation between both cell types [268] . Since the surge of these early notions, our knowledge on the cooperation between the different vascular cells has grown notably. Fig. 8 , depicts the interactions described so far between the 3 cell types. Most of them have been previously described in the corresponding adipokine section. Interesting complex interactions recently proposed are: 1) axis comprised by sympathetic noradrenaline -adipocyte ␤3 receptor -PVAT adiponectin -endothelial adiponectin receptor -NO -smooth muscle cell relaxation [269] ; 2) axis comprised by blood atrial natriuretic peptide -adipocyte ANP receptor -PVAT adiponectin -endothelial adiponectin receptor -NO -smooth muscle cell relaxation [270] ; and 3) axis comprised by smooth muscle cell-derived ROS -blood 4-hydroxynonenal -PVAT adiponectin -endothelial (and smooth muscle cell) NAD(P)H oxidase inhibition -NO -smooth muscle cell relaxation [271] . A final potential route of cell communication is that of endothelial cells towards PVAT adipocytes. A recent report on this route investigated the possible action of endothelium-derived NO on adjacent PVAT compared to that on the media layer. However, it failed to confirm any endothelium -PVAT axis [272] .
Perspectives
The present review intended to provide a wide vision on the footsteps walked to reach the point we are now on vascular physiology research. As the reader has seen, advances took place in a very heterogeneous manner, serendipitous in some occasions and clearly targeted in others. Some times, ancient unconnected knowledge was retrieved and used in a different context to that in which it was originally published. In other occasions, researchers were close to a discovery but just missed it. Attempting to provide future perspectives is a difficult task. Fig. 5 shows that research in vascular pharmacology has followed various waves in which a certain substance or substances were on top. Now we are clearly in the "PVAT wave" and the nearest perspectives will likely concern the physiology and pathophysiology of PVAT-derived substances. The following are some questions raised in the course of this review which may be useful for forthcoming research: Is PVAT-derived NO able to compete with endothelium-derived NO in the control of basal vascular tone, obviously, in vascular beds that carry adipose tissue around? Alternatively, is PVAT-derived NO able to replace endothelial NO in dysfunctional conditions? Is endothelial dysfunction of a certain artery necessarily accompanied by PVAT dysfunction of this particular vessel or, rather, a functional endothelium or PVAT can replace the dysfunctional counterpart? Are PVAT-derived prostaglandins and (or) ADRF (which in practice is an ADHF) able to compete with the endothelial counterparts, prostacyclin, thromboxane A 2 and EDHF? In general terms, to what extent PVAT exerts a regulation in vasomotion as compared to endothelial cells? Is PVAT-derived NO able to relax deendothelialized arteries upon classic endothelial stimulators like acetylcholine or bradykinin or should we look for PVAT-specific NO stimulators? What are the similarities and differences between the biology and regulation of endothelium-derived NO and that of NO released from PVAT? Is ADRF exclusively released from PVAT, or other fat depots do so, and thus, ADRF is an unspecific adipokine? Does the general rule stating that the lesser the caliber or a vessel, the higher the ratio EDHF/NO apply for PVAT as well regarding ADHF versus adipocytic NO? Are there endothelium-derived substances targeted to adjacent PVAT or is smooth muscle the exclusive target of endothelial cells?
